# An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.

> **NCT06753721** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 13 (estimated)

## Conditions studied

- Advanced Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Doxorubicin liposome combined with CapOX and Bevacizumab

## Key facts

- **NCT ID:** NCT06753721
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-31
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-01
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06753721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06753721, "An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06753721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*